Progressive multifocal leukoencephalopathy: Improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 621-625

  Dworkin, Mark S ^a   Wan, Pei Chun T ^a   Hanson, Debra L ^a   Jones, Jeffrey L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACICLOVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; CIDOFOVIR; CYTARABINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VALACICLOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DEMYELINATING DISEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JC VIRUS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK FACTOR; SURVIVAL TIME;

ADOLESCENT; ADULT; AIDS DEMENTIA COMPLEX; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0032827877     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314937     Document Type: Article

References (21)

1. 1. Berger JR, Kaszovitz B, Donovan Post J, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. Ann Intern Med 1987;107:78-87.
2. 2. Petito CK, Cho ES, Lemann W, Navia BA, Price RW. Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. J Neuropathol Exp Neurol 1986;45:635-46.
3. 3. Holman RC, Janssen RS, Buchler JW, Zelasky MT, Hooper WC. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 1991;41:1733-6.
4. 4. Major EO, Ault GS. Progressive multifocal leukoencephalopathy: clinical and laboratory observations on a viral induced demyelinating disease in the immunodeficient patient. Curr Opin Neurol 1995;8:184-90.
5. 5. Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 1998;338:1345-51.
6. 6. Martin-Suarez I, Aguayo Canela M, Merino Munoz D, Pujol de la Llave E. Prolonged survival in patients with progressive multifocal leukoencephalopathy associated with AIDS treated with high doses of zidovudine [in Spanish]. Rev Clin Esp 1994;194:136-8.
7. 7. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992;267:1798-805.
8. 8. Andersen PK, Borgan O, Gill RD, Keiding N. Statistical models based on counting processes. New York: Springer-Verlag, 1993.
9. 9. Grambsch PM, Thernean TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrics 1994;81:515-26.
10. 10. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81, 562-3.
11. 11. Centers for Disease Control and Prevention. Update: trends in AIDS incidence United States, 1996. MMWR Morb Mortal Wkly Rep 1997;46: 861-7.
12. 12. McNaghten, AD, Hanson DL, Jones JL, Ward JW, Dworkin MS. The effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS [abstract 10]. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998.
13. 13. Berger J, Mucke L. Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 1988; 38:1060-5.
14. 14. Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998;44:341-9.
15. 15. Chowdhury M, Kundu M, Khalili K. GA/GC-rich sequence confers Tat responsiveness to human neurotropic virus promoter, JCVL, in cells derived from central nervous system. Oncogene 1993;8:887-92.
16. 16. Baqi M, Kucharczyk W, Walmsley SL. Regression of progressive multifocal encephalopathy with highly active antiretroviral therapy. AIDS 1997;11: 1526-7.
17. 17. Power C, Nath A, Aoki FY, Del Bigio M. Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection. N Engl J Med 1997;336:661-2.
18. 18. Selhorst JB, Ducy KF, Thomas JM, Regelson W. PML: remission and immunologic reversals. Neurology 1978;28:337.
19. 19. Cinque P, Casari S, Bertelli D. Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy [letter]. N Engl J Med 1998;339:848-9.
20. 20. von Einsiedel RW, Fife TD, Aksamit AJ, et al. Progressive multifocal leukoencephalopathy in AIDS: a clinicopathologic study and review of the literature. J Neurol 1993;240:391-406.
21. 21. Karahalios D, Breit R, Dal Canto MC, Levy RM. Progressive multifocal leukoencephalopathy in patients wilh HIV infection: lack of impact of early diagnosis by stereotactic brain biopsy. J Acquired Immun Defic Syndr 1992;5:1030-8.